Steroid 21 Hydroxylase Deficiency Congenital Adrenal Hyperplasia

Pediatric Clinics of North America

Volumn 58, Issue 5, 2011, Pages 1281-1300

  Nimkarn, Saroj ^a   Lin Su, Karen ^a   New, Maria I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

21 hydroxylase; 21 OHD; Adrenal steroid; Congenital adrenal hyperplasia

Indexed keywords

ANDROGEN; CORTICOTROPIN; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; PREDNISONE; STEROID 21 MONOOXYGENASE; CORTICOSTEROID;

21 HYDROXYLASE GENE; ADRENAL GLAND; ADULT; BEDTIME DOSAGE; BONE DENSITY; CHILD; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE INFERTILITY; GENE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE RELEASE; INFERTILITY; MALE INFERTILITY; PATHOPHYSIOLOGY; PRENATAL DIAGNOSIS; PUBERTY; REVIEW; SALT WASTING; STEROID 21 MONOOXYGENASE DEFICIENCY; STEROIDOGENESIS; VIRILIZATION; FEMALE; MALE; METABOLISM; MOLECULAR DIAGNOSIS; PLASTIC SURGERY; PREGNANCY; PREGNANCY COMPLICATION;

ADRENAL CORTEX HORMONES; ADRENAL HYPERPLASIA, CONGENITAL; BONE DENSITY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PREGNANCY; PREGNANCY COMPLICATIONS; RECONSTRUCTIVE SURGICAL PROCEDURES; STEROID 21-HYDROXYLASE;

EID: 80053612997     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2011.07.012     Document Type: Review

References (114)

1. Pang S., Clark A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993, 2:105-139.
2. Therrell B.J., Berenbaum S., Manter-Kapanke V., et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998, 101:583-590.
3. Balsamo A., Cacciari E., Piazzi S., et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics 1996, 98:362-367.
4. Speiser P.W., Dupont B., Rubinstein P., et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985, 37:650-667.
5. Sherman S.L., Aston C.E., Morton N.E., et al. A segregation and linkage study of classical and nonclassical 21-hydroxylase deficiency. Am J Hum Genet 1988, 42:830-838.
6. Ganong W. The central nervous system and the synthesis and release of adrenocorticotrophic hormone. Advances in neuroendocrinology 1963, 92. University of Illinois Press, Urbana. A. Nalbandov (Ed.).
7. Guillemin R., Schally A. Recent advances in the chemistry of neuroendocrine mediators originating in the central nervous system. Advances in neuroendocrinology 1963, 314. University of Illinois Press, Urbana. A. Nalbandov (Ed.).
8. Goto M., Piper Hanley K., Marcos J., et al. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J Clin Invest 2006, 116:953-960.
9. Prader A., Gurtner H.P. Helv Paediatr Acta 1955, 10:397-412.
10. Eugster E.A., Dimeglio L.A., Wright J.C., et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001, 138:26-32.
11. Muirhead S., Sellers E.A., Guyda H. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatr 2002, 141:247-252.
12. Brunelli V., Russo G., Bertelloni S., et al. Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience. J Pediatr Endocrinol Metab 2003, 16(Suppl 2):277-283.
13. Lin-Su K., Vogiatzi M.G., Marshall I., et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005, 90:3318-3325.
14. Quintos J.B., Vogiatzi M.G., Harbison M.D., et al. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001, 86:1511-1517.
15. Jones H., Verkauf B. Congenital adrenal hyperplasia: age at menarche and related events at puberty. Am J Obstet Gynecol 1971, 109:292.
16. Ghali I., David M., David L. Linear growth and pubertal development in treated congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1977, 6:425-436.
17. Trinh L, Nimkarn S, Obeid J, et al. Growth and pubertal characteristics in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. ENDO 2006 The Endocrine Society's 88th Annual Meeting. Boston, Massachusetts, June 24-27, 2006. p. 368.
18. Klingensmith G., Garcia S., Jones H., et al. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 1977, 90:996-1004.
19. Barnes R.B., Rosenfield R.L., Ehrmann D.A., et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994, 79:1328-1333.
20. Long D.N., Wisniewski A.B., Migeon C.J. Gender role across development in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 2004, 17:1367-1373.
21. Meyer-Bahlburg H.F., Dolezal C., Baker S.W., et al. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 2008, 37:85-99.
22. Hines M., Brook C., Conway G.S. Androgen and psychosexual development: core gender identity, sexual orientation and recalled childhood gender role behavior in women and men with congenital adrenal hyperplasia (CAH). J Sex Res 2004, 41:75-81.
23. Mulaikal R.M., Migeon C.J., Rock J.A. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 1987, 316:178-182.
24. Premawardhana L., Hughes I., Read G., et al. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 1997, 46:327-332.
25. Prader A., Zachmann M., Illig R. Normal spermatogenesis in adult males with congenital adrenal hyperplasia after discontinuation of therapy. Congenital adrenal hyperplasia 1977, 397. University Park Press, Baltimore (MD). P. Lee, L. Platnick, A. Kowarski (Eds.).
26. Stewart J. A fertile male with untreated congenital adrenal hyperplasia. Acta Endocrinol Suppl 1960, 51:661.
27. Urban M., Lee P., Migeon C. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 1978, 299:1392.
28. Cabrera M., Vogiatzi M., New M. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001, 86:3070-3080.
29. Sugino Y., Usui T., Okubo K., et al. Genotyping of congenital adrenal hyperplasia due to 21-hydroxylase deficiency presenting as male infertility: case report and literature review. J Assist Reprod Genet 2006, 23:377-380.
30. Bonaccorsi A., Adler I., Figueiredo J. Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. Fertil Steril 1987, 47:664-670.
31. Claahsen-van der Grinten H.L., Sweep F.C., Blickman J.G., et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2007, 157:339-344.
32. Molitor J., Chertow B., Fariss B. Long-term follow-up of a patient with congenital adrenal hyperplasia and failure of testicular development. Fertil Steril 1973, 24:319.
33. Blumberg-Tick J., Boudou P., Nahoul K., et al. Testicular tumors in congenital adrenal hyperplasia: steroid measurements from adrenal and spermatic veins. J Clin Endocrinol Metab 1991, 73:1129-1133.
34. Claahsen-van der Grinten H.L., Otten B.J., Hermus A.R., et al. Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage. Fertil Steril 2008, 89:597-601.
35. Schoen E., DiRaimondo V., Dominguez O. Bilateral testicular tumors complicating congenital adrenocortical hyperplasia. J Clin Endocrinol Metab 1961, 21:518.
36. Miller E., Murray H. Congenital adrenocortical hyperplasia: case previously reported as " bilateral interstitial cell tumor of the testicle" J Clin Endocrinol Metab 1962, 22:655.
37. Glenn J., Boyce W. Adrenogenitalism with testicular adrenal rests simulating interstitial cell tumor. J Urol 1963, 89:456.
38. Srikanth M., West B., Ishitani M., et al. Benign testicular tumors in children with congenital adrenal hyperplasia. J Pediatr Surg 1992, 27:639-641.
39. Rutgers J., Young R., Scully R. The testicular " tumor" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol 1988, 12:503-513.
40. Wilkins L., Crigler J., Silverman S., et al. Further studies on the treatment of congenital adrenal hyperplasia with cortisone. II. The effects of cortisone on sexual and somatic development, with a hypothesis concerning the mechanism of feminization. J Clin Endocrinol Metab 1952, 12:277.
41. Klein R. Evidence for and evidence against the existence of a salt-losing hormone. J Pediatr 1960, 57:452.
42. Kowarski A., Finkelstein J.W., Spaulding J.S., et al. Aldosterone secretion rate in congenital adrenal hyperplasia. A discussion of the theories on the pathogenesis of the salt-losing form of the syndrome. J Clin Invest 1965, 44:1505-1513.
43. Kuhnle U., Land M., Ulick S. Evidence for the secretion of an antimineralocorticoid in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1986, 62:934-940.
44. Merke D., Chrousos G., Eisenhofer G., et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 2000, 343:1362-1368.
45. Stoner E., Dimartino-Nardi J., Kuhnle U., et al. Is salt-wasting in congenital adrenal hyperplasia due to the same gene as the fasciculata defect?. Clin Endocrinol (Oxf) 1986, 24:9-20.
46. Luetscher J.A. Studies of aldosterone in relation to water and electrolyte balance in man. Recent Prog Horm Res 1956, 12:175.
47. Speiser P.W., Agdere L., Ueshiba H., et al. Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase. N Engl J Med 1991, 324:145-149.
48. Nimkarn S., New M.I. Prenatal diagnosis and treatment of congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Nat Clin Pract Endocrinol Metab 2007, 3:405-413.
49. New M.I. Nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006, 91:4205-4214.
50. New M.I. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006, 91:4205-4214.
51. Kashimada K., Ono M., Onishi T., et al. Clinical course of patients with nonclassical 21-hydroxylase deficiency (21-OHD) diagnosed in infancy and childhood. Endocr J 2008, 55:397-404.
52. Fanta M., Cibula D., Vrbikova J. Prevalence of nonclassic adrenal hyperplasia (NCAH) in hyperandrogenic women. Gynecol Endocrinol 2008, 24:154-157.
53. Escobar-Morreale H.F., Sanchon R., San Millan J.L. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008, 93:527-533.
54. Claahsen-van der Grinten H.L., Otten B.J., Sweep F.C., et al. Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. Fertil Steril 2007, 88. 705, e5-8.
55. Jaaskelainen J., Tiitinen A., Voutilainen R. Sexual function and fertility in adult females and males with congenital adrenal hyperplasia. Horm Res 2001, 56:73-80.
56. Clayton P.E., Miller W.L., Oberfield S.E., et al. Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002, 58:188-195.
57. Mokshagundam S., Surks M. Congenital adrenal hyperplasia diagnosed in a man during workup for bilateral adrenal masses. Arch Intern Med 1993, 153:1389-1391.
58. Jaresch S., Kornely E., Kley H., et al. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992, 74:685-689.
59. Wilson R.C., Mercado A.B., Cheng K.C., et al. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 1995, 80:2322-2329.
60. Dupont B., Oberfield S.E., Smithwick E.M., et al. Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet 1977, 2:1309-1312.
61. Nebert D.W., Nelson D.R., Coon M.J. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991, 10:1-14.
62. White P.C., New M.I., Dupont B. Structure of the human steroid 21-hydroxylase genes. Proc Natl Acad Sci U S A 1986, 83:5111-5115.
63. Stenson P.D., Ball E.V., Mort M., et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003, 21:577-581.
64. Tusie-Luna M.T., Speiser P.W., Dumic M., et al. A mutation (Pro-30 to Leu) in CYP21 represents a potential nonclassic steroid 21-hydroxylase deficiency allele. Mol Endocrinol 1991, 5:685-692.
65. Speiser P.W., New M.I., White P.C. Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14, DR1. N Engl J Med 1988, 319:19-23.
66. Helmberg A., Tusie-Luna M., Tabarelli M., et al. R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversions. Mol Endocrinol 1992, 6:1318-1322.
67. Owerbach D., Sherman L., Ballard A.L., et al. Pro-453 to Ser mutation in CYP21 is associated with nonclassic steroid 21-hydroxylase deficiency. Mol Endocrinol 1992, 6:1211-1215.
68. White P.C., New M.I., Dupont B. HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A 1984, 81:7505-7509.
69. Higashi Y., Tanae A., Inoue H., et al. Aberrant splicing and missense mutations cause steroid 21-hydroxylase [P-450(C21)] deficiency in humans: possible gene conversion products. Proc Natl Acad Sci U S A 1988, 85:7486-7490.
70. White P.C., Tusie-Luna M.T., New M.I., et al. Mutations in steroid 21-hydroxylase (CYP21). Hum Mutat 1994, 3:373-378.
71. Tusie-Luna M., Traktman P., White P.C. Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 1990, 265:20916-20922.
72. Amor M., Parker K.L., Globerman H., et al. Mutation in the CYP21B gene (Ile-172-Asn) causes steroid 21-hydroxylase deficiency. Proc Natl Acad Sci U S A 1988, 85:1600-1607.
73. Globerman H., Amor M., Parker K.L., et al. Nonsense mutation causing steroid 21-hydroxylase deficiency. J Clin Invest 1988, 82:139-144.
74. Chiou S.H., Hu M.C., Chung B.C. A missense mutation at Ile172-Asn or Arg356-Trp causes steroid 21-hydroxylase deficiency. J Biol Chem 1990, 265:3549-3552.
75. Wedell A., Luthman H. Steroid 21-hydroxylase (P450c21): a new allele and spread of mutations through the pseudogene. Hum Genet 1993, 91:236-240.
76. Speiser P.W., Dupont J., Zhu D., et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992, 90:584-595.
77. Wedell A., Ritzen E.M., Haglund-Stengler B., et al. Steroid 21-hydroxylase deficiency: three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations. Proc Natl Acad Sci U S A 1992, 89:7232-7236.
78. Krone N., Braun A., Roscher A., et al. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 2000, 85:p1059-p1065.
79. Chemaitilly W., Betensky B., Marshal I., et al. Case report: the natural history and genotype-phenotype nonconcordance of HLA identical siblings with the same mutations of the 21-hydroxylase gene. J Pediatr Endocrinol Metab 2005, 18:143-154.
80. Rohana A.G., Ming W., Norlela S., et al. Functioning adrenal adenoma in association with congenital adrenal hyperplasia. Med J Malaysia 2007, 62:158-159.
81. Jansen M., Wit J.M., van den Brande J.L. Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth. Acta Paediatr Scand 1981, 70:229-233.
82. Forest M.G., Dorr H.G. Prenatal therapy in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: retrospective follow-up study of 253 treated pregnancies in 215 families. Endocrinologist 2003, 13:252-259.
83. Schachter S.C. Handedness in women with intrauterine exposure to diethystilbestrol. Neuropsychologia 1994, 32:619-623.
84. Schnitzer J., Donahoe P. Surgical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001, 30:137-154.
85. Crouch N.S., Liao L.M., Woodhouse C.R., et al. Sexual function and genital sensitivity following feminizing genitoplasty for congenital adrenal hyperplasia. J Urol 2008, 179:634-638. [Epub 2007 Dec 21].
86. Gastaud F., Bouvattier C., Duranteau L., et al. Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. Clin Endocrinol Metab 2007, 92:1391-1396.
87. Nordenskjold A., Holmdahl G., Frisen L., et al. Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2008, 93:380-386.
88. Mazziotti G., Giustina A., Canalis E., et al. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. Arq Bras Endocrinol Metabol 2007, 51:1404-1412.
89. Falhammar H., Filipsson H., Holmdahl G., et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92:4643-4649.
90. King J.A., Wisniewski A.B., Bankowski B.J., et al. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006, 91:865-869.
91. Stikkelbroeck N., Oyen W., van der Wilt G.J., et al. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2003, 88:1036-1042.
92. Christiansen P., Molgaard C., Muller J. Normal bone mineral content in young adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2004, 61:133-136.
93. Cornean R.E., Hindmarsh P.C., Brook C.G. Obesity in 21-hydroxylase deficient patients. Arch Dis Child 1998, 78:261-263.
94. Charmandari E., Chrousos G.P. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome?. Ann N Y Acad Sci 2006, 1083:37-53.
95. Volkl T.M., Simm D., Beier C., et al. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 2006, 117:e98-e105.
96. Speiser P.W., Serrat J., New M.I., et al. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992, 75:1421-1424.
97. Charmandari E., Weise M., Bornstein S., et al. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. J Clin Endocrinol Metab 2002, 87:2114-2120.
98. Sartorato P., Zulian E., Benedini S., et al. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92:1015-1018.
99. Falhammar H., Filipsson H., Holmdahl G., et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92:110-116.
100. Roche E.F., Charmandari E., Dattani M.T., et al. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clin Endocrinol (Oxf) 2003, 58:589-596.
101. Weise M., Drinkard B., Mehlinger S.L., et al. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab 2004, 89:3679-3684.
102. Green-Golan L., Yates C., Drinkard B., et al. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glycemic control during prolonged moderate-intensity exercise. J Clin Endocrinol Metab 2007, 92:3019-3024.
103. Burton P.J., Waddell B.J. Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Biol Reprod 1999, 60:234-240.
104. Rennick G.J. Use of systemic glucocorticosteroids in pregnancy: be alert but not alarmed. Australas J Dermatol 2006, 47:34-36.
105. Carlson A.D., Obeid J.S., Kanellopoulou N., et al. Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. Diagnosis and treatment of the unborn child 1999, 75-84. Idelson-Gnocchi Ltd. Publisher, Reddick (FL). M.I. New (Ed.).
106. New M., Carlson A., Obeid J., et al. Update: Prenatal diagnosis for congenital adrenal hyperplasia in 595 pregnancies. Endocrinologist 2003, 13:233-239.
107. Goldman A., Sharpior B., Katsumata M. Human foetal palatal corticoid receptors and teratogens for cleft palate. Nature 1978, 272:464-466.
108. Nimkarn S., New M.I. Prenatal diagnosis and treatment of congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Nat Clin Pract Endocrinol Metab 2007, 3:405-413.
109. Pang S., Clark A.T., Freeman L.O., et al. Maternal side-effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992, 76:249-253.
110. Lajic S., Wedell A., Bui T., et al. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1998, 83:3872-3880.
111. Meyer-Bahlburg H.F., Dolezal C., Baker S.W., et al. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metab 2004, 89:610-614.
112. Hirvikoski T., Nordenstrom A., Lindholm T., et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 2007, 92:542-548.
113. Hirvikoski T., Nordenstrom A., Lindholm T., et al. Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems?. Eur J Endocrinol 2008, 159:309-316.
114. Kruse B., Riepe F.G., Krone N., et al. Congenital adrenal hyperplasia-how to improve the transition from adolescence to adult life. Exp Clin Endocrinol Diabetes 2004, 112:343-355.